Tizanidine Tablet
Product Images NDC 76420-228

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 76420-228). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Container1)

Labels for Tizanidine Tablets, USP 2 mg oral tablets packaged by Enovachem Pharmaceuticals, consisting of three distinct NDCs: 76420-228-30 (30 count), 76420-228-60 (60 count), and 76420-228-90 (90 count). Manufactured by Dr. Reddy's Laboratories Limited, each label includes barcodes, QR codes, and storage instructions advising controlled room temperature.*

FDA Label Image

Image Description (Container2)

Packaging labels for Tizanidine Tablets USP 4 mg by Enovachem Pharmaceuticals, available in quantities of 30, 60, and 90 tablets. Labels include NDC numbers 76420-229-30, 76420-229-60, and 76420-229-90 respectively. Manufactured by Dr. Reddy's Laboratories Limited, the tablets are white to off-white, oval, flat with beveled edges and debossed.*

FDA Label Image

Image Description (Fig1)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours) after dosing. It compares 2 x 4 mg Tizanidine tablets and capsules taken with and without food, plotted from 0 to 24 hours post-dose, illustrating differences in concentration-time profiles for each condition.*

FDA Label Image

Image Description (Fig2)

Line graph depicting improvement in Ashworth Score over time post-dose, comparing 16 mg and 8 mg doses of tizanidine against placebo. The x-axis represents hours post-dose (0 to 6), while the y-axis shows improvement in Ashworth Score, with higher scores indicating greater improvement. Error bars indicate variability in the measurements.*

FDA Label Image

Image Description (Fig3)

A line graph showing improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation). It compares the mean improvement between groups receiving Tizanidine (mean dose 28.8 mg) and placebo. Tizanidine shows greater improvement at all points compared to placebo, with error bars indicating variability.*

FDA Label Image

Image Description (Structure)

Chemical structure of Tizanidine hydrochloride showing its molecular framework including fused rings with nitrogen and chlorine atoms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.